Ambite I, Wan M, Tran H, Nazari A, Chaudhuri A, Krintel C
Sci Rep. 2025; 15(1):6778.
PMID: 40000737
PMC: 11861601.
DOI: 10.1038/s41598-025-88093-2.
Kovalski J, Sarioglu G, Subramanyam V, Hernandez G, Rademaker G, Oses-Prieto J
Nat Cell Biol. 2025; 27(3):518-529.
PMID: 39905246
DOI: 10.1038/s41556-024-01604-7.
Seres M, Spacayova K, Sulova Z, Spaldova J, Breier A, Pavlikova L
Cancers (Basel). 2025; 17(2).
PMID: 39858030
PMC: 11763799.
DOI: 10.3390/cancers17020248.
Li M, Li J, He C, Jiang G, Ma D, Guan H
J Biol Chem. 2024; 301(1):108030.
PMID: 39615685
PMC: 11730240.
DOI: 10.1016/j.jbc.2024.108030.
Zhai W, Yang W, Ge J, Xiao X, Wu K, She K
Biol Direct. 2024; 19(1):94.
PMID: 39415271
PMC: 11483991.
DOI: 10.1186/s13062-024-00512-y.
Transcription factor 4 is a key mediator of oncogenesis in neuroblastoma by promoting MYC activity.
Aljouda N, Shrestha D, DeVaux C, Olsen R, Alleboina S, Walker M
Mol Oncol. 2024; 19(3):808-824.
PMID: 39119816
PMC: 11887674.
DOI: 10.1002/1878-0261.13714.
Exploring the origins of neurodevelopmental proteasomopathies associated with cardiac malformations: are neural crest cells central to certain pathological mechanisms?.
Vignard V, Baruteau A, Toutain B, Mercier S, Isidor B, Redon R
Front Cell Dev Biol. 2024; 12:1370905.
PMID: 39071803
PMC: 11272537.
DOI: 10.3389/fcell.2024.1370905.
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer.
Klomp J, Diehl J, Klomp J, Edwards A, Yang R, Morales A
Science. 2024; 384(6700):eadk0850.
PMID: 38843329
PMC: 11301400.
DOI: 10.1126/science.adk0850.
CRL2 and CRL1 cooperatively mediate c-Myc degradation.
Motomura S, Yumimoto K, Tomonaga T, Nakayama K
Oncogene. 2024; 43(25):1917-1929.
PMID: 38698266
DOI: 10.1038/s41388-024-03048-7.
AF1q is a universal marker of neuroblastoma that sustains N-Myc expression and drives tumorigenesis.
Oskouian B, Lee J, Asgharzadeh S, Khan R, Zhang M, Weisbrod J
Oncogene. 2024; 43(16):1203-1213.
PMID: 38413795
PMC: 11014797.
DOI: 10.1038/s41388-024-02980-y.
New insights in ubiquitin-dependent Wnt receptor regulation in tumorigenesis.
Tsukiyama T
In Vitro Cell Dev Biol Anim. 2024; 60(5):449-465.
PMID: 38383910
PMC: 11126518.
DOI: 10.1007/s11626-024-00855-w.
Bromodomain Protein-directed Agents and MYC in Small Cell Lung Cancer.
Hamilton G, Stickler S, Rath B
Curr Cancer Drug Targets. 2024; 24(9):930-940.
PMID: 38275056
DOI: 10.2174/0115680096272757231211113206.
Aurora B facilitates cholangiocarcinoma progression by stabilizing c-Myc.
Liu K, Zhou X, Huang F, Liu L, Xu Z, Gao C
Animal Model Exp Med. 2024; 7(5):626-640.
PMID: 38247322
PMC: 11528393.
DOI: 10.1002/ame2.12370.
LINC00629, a HOXB4-downregulated long noncoding RNA, inhibits glycolysis and ovarian cancer progression by destabilizing c-Myc.
Liu J, Zhu Y, Wang H, Han C, Wang Y, Tang R
Cancer Sci. 2024; 115(3):804-819.
PMID: 38182548
PMC: 10920983.
DOI: 10.1111/cas.16049.
MYC function and regulation in physiological perspective.
Jha R, Kouzine F, Levens D
Front Cell Dev Biol. 2023; 11:1268275.
PMID: 37941901
PMC: 10627926.
DOI: 10.3389/fcell.2023.1268275.
Unraveling MYC's Role in Orchestrating Tumor Intrinsic and Tumor Microenvironment Interactions Driving Tumorigenesis and Drug Resistance.
Doha Z, Sears R
Pathophysiology. 2023; 30(3):400-419.
PMID: 37755397
PMC: 10537413.
DOI: 10.3390/pathophysiology30030031.
SPOP targets the immune transcription factor IRF1 for proteasomal degradation.
Schwartz I, Vunjak M, Budroni V, Cantoran Garcia A, Mastrovito M, Soderholm A
Elife. 2023; 12.
PMID: 37622993
PMC: 10491434.
DOI: 10.7554/eLife.89951.
Cordycepin (3'dA) Induces Cell Death of AC133 Leukemia Cells via Re-Expression of and Down-Modulation of .
Abazari N, Stefanucci M, Bossi L, Trojani A, Cairoli R, Beghini A
Cancers (Basel). 2023; 15(15).
PMID: 37568748
PMC: 10417454.
DOI: 10.3390/cancers15153931.
Nucleus-specific RNAi nanoplatform for targeted regulation of nuclear lncRNA function and effective cancer therapy.
Huang Z, Liu S, Lu N, Xu L, Shen Q, Huang Z
Exploration (Beijing). 2023; 2(5):20220013.
PMID: 37325502
PMC: 10191018.
DOI: 10.1002/EXP.20220013.
Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells.
Tang M, Crown J, Duffy M
Invest New Drugs. 2023; 41(4):541-550.
PMID: 37233863
PMC: 10447602.
DOI: 10.1007/s10637-023-01368-1.